Many roads lead to MPN.
In this issue of Blood, Lundberg et al correlate the presence of known mutations in patients with myeloproliferative neoplasms (MPNs) with clinical outcome, thereby proposing a molecular risk stratification.
UNIVERSITY MEDICAL CENTER FREIBURG.
Heike L
HL
Pahl
D060965:Clonal Evolution; D005260:Female; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000473:pathology*